Multi-Chimeric Cell Fusion for GvHD-Reduced Stem Cell Transplantation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current stem cell transplantation methods face limitations such as the scarcity of matched donors, high mortality and morbidity due to conditioning regimens, and the risk of graft-versus-host disease (GvHD), which hinder the widespread application of hematopoietic stem cell transplantation for treating immune deficiencies and genetic disorders.
Innovation Solution
Development of multi-chimeric cells through the ex vivo fusion of hematopoietic stem cells, mesenchymal stem cells, myoblasts, pericytes, or satellite cells from multiple donors, which express HLA antigens and can be administered to mitigate immunosuppression side effects and enhance engraftment without GvHD.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If allogeneic stem cell transplantation is performed to treat immune deficiencies and genetic disorders, then treatment efficacy is improved, but mortality and morbidity increase due to conditioning regimens and graft-versus-host disease
Solution Approach 1:
The patent combines hematopoietic stem cells from multiple unrelated donors into a single multi-chimeric cell. This merged cell expresses HLA antigens from all donor cells, enabling it to function as a universal donor that can treat multiple patients simultaneously while avoiding the need for individual matched donors and reducing GvHD risk through controlled differentiation
Solution Approach 2:
The multi-chimeric cell is designed to be universally applicable across multiple patients by incorporating HLA antigens from multiple unrelated donors. This single cell type can serve as a universal donor for various immune deficiencies and genetic disorders, eliminating the need for patient-specific donor matching and expanding treatment availability
2Adaptability or versatility
If matched unrelated HSC transplantation is performed to expand treatment options, then availability of treatment is improved, but mortality and morbidity increase due to toxic effects of conditioning regimens and GvHD
Solution Approach 1:
The patent merges stem cells from multiple unrelated donors into one multi-chimeric cell, creating a universal donor that expands treatment availability without requiring individual matched donors. This approach eliminates the need for extensive donor searching and matching while reducing GvHD risk through the controlled differentiation of the fused cell
Solution Approach 2:
The invention changes the fundamental parameter of donor matching by transitioning from single-donor HLA matching to multi-donor HLA antigen expression in a single cell. This parameter change allows the treatment to be applied across multiple patient populations without requiring traditional matched unrelated donor searches, thereby expanding availability while controlling immunological compatibility
3Adaptability or versatility
If traditional stem cell transplantation methods are used to treat genetic disorders, then treatment coverage is limited by donor availability, but the complexity of finding matched donors increases
Solution Approach 1:
The multi-chimeric cell serves as a universal donor that can treat multiple different genetic disorders and immune deficiencies simultaneously. By incorporating HLA antigens from multiple unrelated donors, this single cell type replaces the need for multiple specific matched donors, thereby expanding treatment coverage while simplifying the donor selection process
Solution Approach 2:
The patent combines stem cells from multiple unrelated donors into one multi-chimeric cell, merging the donor pool into a single therapeutic product. This merging eliminates the complex process of searching for and matching individual donors for each patient, as the multi-chimeric cell inherently contains the necessary HLA diversity to treat various patient populations
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The multi-chimeric cells effectively treat immune deficiencies and genetic disorders while reducing the risk of GvHD and improving engraftment, offering a more effective and safer transplantation method.
Implementation Method 1
a multi-chimeric cell composed of a fusion of three or more hematopoietic stem cells, mesenchymal stem cells, myoblasts, pericytes, satellite cells
Data Source
AI summary
A multi-chimeric cell created by ex vivo fusion of three or more hematopoietic stem cells, mesenchymal stem cells, myoblasts, pericytes, or satellite cells, or a combination thereof, from three or more different donors is provided, as is the use of these cells in transplant therapy and treatment of immune deficiency and genetic disorders.